Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
967.4 USD | +1.22% | +3.38% | +10.36% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 27.13 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.08% | 105B | B+ | ||
+2.73% | 108B | B+ | ||
+1.57% | 23.46B | B | ||
-12.05% | 21.72B | B+ | ||
-7.05% | 18.64B | A- | ||
-37.64% | 17.45B | A- | ||
-7.28% | 17.19B | B | ||
+6.12% | 13.99B | C+ | ||
+35.93% | 12.53B | C+ | ||
+333.10% | 8.81B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- REGN Stock
- Ratings Regeneron Pharmaceuticals, Inc.